Normal Cholesterol. But Heart Disease. Here Is What the Test Missed.

This is one of the most common conversations in clinical cardiology. A patient arrives, often after a concerning finding on a scan or a stress test, sometimes after a frank cardiac event. He had a lipid panel at his last annual physical. His LDL was 102. His physician told him his cholesterol was fine. He believed it, because the number was right there in the normal range.

His coronary artery calcium score is 347. His proximal LAD has a 40 percent stenosis. He is 54 years old.

The LDL was not lying. It measured accurately what it measures. What it does not measure is how many LDL particles were circulating in his blood. And in this man, with his waist circumference of 43 inches and his triglycerides of 210, there were a great many of them.

The Mechanism

The fundamental problem with LDL cholesterol as a risk measure is that it is a mass measurement, not a particle count.

LDL-C tells you how much cholesterol is carried inside the LDL particles in a unit of your blood. It does not tell you how many particles are carrying that cholesterol. This distinction does not matter when particle size is uniform. It matters enormously when particle size varies across a population, as it does.

Each LDL particle carries a variable amount of cholesterol depending on its size. Large, buoyant LDL particles, the kind predominant in lean, metabolically healthy adults, carry more cholesterol per particle. Small, dense LDL particles, the kind produced in abundance in patients with insulin resistance and elevated triglycerides, carry substantially less cholesterol per particle.

Two men can have an identical LDL of 105 mg/dL. In the first man, that cholesterol mass is distributed across roughly 900 large particles. In the second man, it is distributed across roughly 1,600 small, dense particles. Their LDL-C is identical. The second man’s cardiovascular risk is substantially higher. His particle count is nearly double. Each of those particles is capable of crossing the endothelium, being retained in the subintimal space, becoming oxidized, and initiating a plaque.

ApoB measures the particles directly. Every atherogenic lipoprotein, every LDL, VLDL, and IDL particle, carries exactly one molecule of apolipoprotein B on its outer surface. This is structural biology: one ApoB per particle, without exception. An ApoB of 120 mg/dL means a calculable, specific number of atherogenic particles in circulation. An ApoB of 60 means half as many. The number of particles is what determines how quickly plaque accumulates in the arterial wall. 5 / Solid

The 2019 European Society of Cardiology and European Atherosclerosis Society guidelines, after reviewing decades of prospective epidemiological data, Mendelian randomization studies, and randomized trial subgroup analyses, concluded formally that ApoB is a more accurate measure of cardiovascular risk than LDL cholesterol. The guidelines designated ApoB as the preferred lipid treatment target in high-risk patients. (Mach et al., European Heart Journal, 2020, doi: 10.1093/eurheartj/ehz455)

What the Evidence Shows

The statistic that frames this most starkly: studies of patients presenting with acute myocardial infarction consistently find that 40 to 50 percent have LDL cholesterol in the normal range at the time of the event. This finding has been replicated across multiple large hospital cohort studies and has been noted in reviews published in the Journal of the American College of Cardiology and elsewhere. Normal LDL at the time of an MI is not the exception. It describes nearly half of all MI patients.

The MESA study (Multi-Ethnic Study of Atherosclerosis), which followed more than 6,000 adults without cardiovascular disease at enrollment, documented the predictive superiority of ApoB over LDL-C in prospective event tracking. In the analysis published in JAMA Cardiology in 2022 (doi: 10.1001/jamacardio.2021.5856), ApoB predicted incident cardiovascular events more accurately than LDL-C across all demographic subgroups. The advantage was most pronounced precisely in the patients for whom the standard panel is most likely to be misleading: those with the metabolic syndrome phenotype of abdominal adiposity, elevated triglycerides, and low HDL. 5 / Solid

The AMORIS study, a Swedish prospective cohort of 175,000 individuals published in the Lancet in 2001 by Walldius et al., was one of the first population-scale demonstrations that ApoB was a superior predictor of fatal myocardial infarction compared to LDL-C or total cholesterol. The study covered a broad Swedish population over extended follow-up and found that ApoB outperformed LDL in both men and women across all age groups studied.

The genetic evidence reinforces the mechanistic picture. Mendelian randomization studies use naturally occurring genetic variants that lower LDL-C or ApoB to estimate the causal effect of each marker on cardiovascular events. An analysis by Ference et al. published in JAMA in 2019, using genetic data from more than 300,000 individuals across multiple biobanks, found that the causal relationship between ApoB and cardiovascular events was stronger than the equivalent relationship with LDL-C after accounting for variation in particle size and cholesterol content per particle. The genes that lower ApoB without proportionately lowering LDL-C showed cardiovascular benefit that the LDL reduction alone did not predict. (doi: 10.1001/jama.2019.14310)

A 2010 analysis published in Circulation by Cromwell et al. used data from 5,124 patients with established coronary heart disease and demonstrated that in patients where LDL-C and LDL particle number (measured by NMR spectroscopy, a related but different method from ApoB) were discordant, LDL particle number predicted recurrent cardiovascular events and LDL-C did not. The discordant group comprised a substantial fraction of the patient population.

When Discordance Is Most Dangerous

The gap between what LDL predicts and what ApoB predicts is widest in a specific and identifiable metabolic phenotype. Understanding this phenotype is the most clinically useful thing a patient can take from this article.

The phenotype: waist circumference above 40 inches in men. Fasting triglycerides above 150 mg/dL, typically 150 to 350 mg/dL. HDL below 45 mg/dL, often below 40. Fasting glucose in the upper portion of the normal range, 90 to 99 mg/dL, or mildly elevated. Blood pressure at or above 130/80. This is the metabolic syndrome phenotype, which the National Cholesterol Education Program defines by the presence of three or more of these five criteria. It affects approximately 35 percent of US adults.

In these patients, the liver is operating under conditions of insulin resistance. It produces more VLDL particles, and those particles are enriched with triglycerides and relatively cholesterol-poor. As these VLDL particles are remodeled in circulation by lipoprotein lipase and other enzymes, they generate small, dense, cholesterol-poor LDL particles. The LDL-C is often in the normal range, because each particle is carrying less cholesterol than a large particle would. The ApoB is elevated, because there are many of these small particles. The cardiovascular risk is elevated, because the arterial wall sees the particles.

A man with this phenotype sitting in a primary care office, having just been told his LDL of 108 looks fine, is being given an incomplete picture. His cardiologist sees this pattern repeatedly.

The Residual Risk Problem: What Remains After LDL Is Controlled

Suppose a patient does get an ApoB measurement, the result is borderline, and a statin is started. LDL-C falls from 108 to 62. ApoB improves. The cardiologist is satisfied. Is the risk eliminated?

Not entirely. Cardiovascular medicine uses the term residual risk to describe the cardiovascular events that continue to occur in patients whose LDL has been aggressively lowered. Even in the landmark statin trials that drove LDL to 55 mg/dL or below, substantial numbers of patients still experienced myocardial infarctions. Treating LDL is necessary. It is not sufficient for every patient. Several non-LDL pathways drive atherogenesis in parallel, and the standard lipid panel does not measure any of them.

Triglyceride-rich lipoprotein remnants. When fasting triglycerides are elevated, typically above 150 mg/dL and increasingly consequential above 200, a large pool of VLDL and VLDL remnant particles circulates in the bloodstream. These particles are atherogenic for the same structural reason that LDL particles are: each carries a single ApoB molecule and is capable of crossing the endothelium and being retained in the arterial wall. The difference is that VLDL remnants are substantially larger than LDL and, under conditions of arterial inflammation, may be particularly effective at initiating plaque. The REDUCE-IT trial, which randomized over 8,000 high-risk patients with elevated triglycerides to high-dose icosapentaenoic acid (EPA) versus placebo, found a 25 percent relative risk reduction in major adverse cardiovascular events despite already well-controlled LDL. (Bhatt et al., New England Journal of Medicine, 2019, doi: 10.1056/NEJMoa1812792) The benefit appeared to be concentrated in patients with the highest triglyceride-rich lipoprotein burden.

Lipoprotein(a). Lp(a) is structurally similar to LDL: it is an LDL-like particle carrying an ApoB molecule plus an additional protein called apolipoprotein(a) attached by a disulfide bond. The apolipoprotein(a) chain interferes with fibrinolysis, promotes thrombosis, and may make the particle more inflammatory per unit than standard LDL. Lp(a) levels are approximately 80 to 90 percent genetically determined, are not substantively lowered by statins, and are not captured by the standard lipid panel. A patient can have LDL-C of 95 mg/dL and Lp(a) of 180 nmol/L and present with premature coronary artery disease in his mid-forties. The elevated Lp(a) is the residual risk that the LDL measurement missed entirely. Epidemiological data from over 30 prospective cohort studies, analyzed in a 2009 meta-analysis by Erqou et al. in JAMA, found that Lp(a) was independently associated with cardiovascular disease after adjustment for LDL and other established risk factors, with those in the top tertile of Lp(a) carrying approximately 1.5 to two times the risk of those in the bottom tertile. (doi: 10.1001/jama.2009.1063) Major guidelines, including those of the European Atherosclerosis Society, now recommend at least one Lp(a) measurement in every adult as part of lifetime cardiovascular risk assessment. 5 / Solid

High-sensitivity C-reactive protein. Inflammation drives plaque progression and, critically, plaque rupture, which is the proximate cause of most myocardial infarctions. High-sensitivity CRP (hsCRP) is the most widely available clinical marker of systemic vascular inflammation. The JUPITER trial randomized over 17,000 adults with LDL below 130 mg/dL but elevated hsCRP above 2 mg/L to rosuvastatin or placebo and found a 44 percent reduction in major cardiovascular events in the treatment arm. The patient population was specifically selected to represent individuals whose standard LDL appeared acceptable but whose inflammatory burden conferred elevated risk. (Ridker et al., New England Journal of Medicine, 2008, doi: 10.1056/NEJMoa0807646) An hsCRP above 2 mg/L in a patient with an LDL of 100 mg/dL is not reassuring evidence of low risk. It may represent the dominant active risk pathway.

Small dense LDL discordance. As described in the mechanism section, patients with insulin resistance and elevated triglycerides produce an overabundance of small, cholesterol-poor LDL particles. Their LDL-C underestimates particle burden. ApoB corrects for this. But in clinical practice, many patients who have not had ApoB measured are walking around with a lipid report that describes their LDL as 98 mg/dL without any indication that those 98 milligrams are distributed across a very large number of small particles, each capable of driving atherogenesis, rather than across a smaller number of large ones.

The clinical implication of residual risk is not that statin therapy is inadequate. It is that a complete cardiovascular risk assessment in a patient with “normal cholesterol” must look beyond LDL-C. ApoB addresses the particle number problem. Lp(a) addresses the genetic residual risk. hsCRP addresses the inflammatory pathway. None of these are exotic or investigational measurements. All three are available through standard clinical laboratories. The question in each case is only whether the clinician and patient knew to ask.

Coronary Artery Calcium Scoring: The Test That Resolves the Paradox

There is a more direct answer to the question at the center of this article: a patient wants to know whether, despite a normal LDL, atherosclerotic plaque has already developed in his coronary arteries. No blood test answers this with certainty. The coronary artery calcium (CAC) score does.

The CAC score is obtained through a low-dose, non-contrast computed tomography scan of the chest. The scanner detects calcium deposits within coronary artery plaque. The result is reported as an Agatston score, which reflects both the density and the area of calcium detected. The scan delivers a radiation dose of approximately one to two millisieverts, roughly equivalent to the natural background radiation exposure of six months to a year, and does not require contrast injection, fasting, or a catheter. Total scan time is under 15 minutes.

The Agatston score is interpreted in absolute terms and in comparison to age- and sex-matched population percentiles:

• CAC = 0: No detectable coronary calcium. This is strongly reassuring. Data from the MESA study show that a CAC of zero in a patient aged 45 to 75 is associated with a 10-year cardiovascular event rate below two percent, even in patients with traditional risk factors. In a 55-year-old man with normal LDL and borderline metabolic risk, a CAC of zero allows the clinician to defer aggressive pharmacotherapy with confidence and revisit risk assessment in three to five years.

• CAC 1 to 99: Early plaque is present but limited. This confirms that atherogenesis has begun and quantifies initial burden. Risk stratification tools, including the ACC/AHA Pooled Cohort Equations, can be recalibrated around this confirmed anatomical finding.

• CAC 100 to 299: Moderate plaque burden. In guidelines language, this is the zone where statin therapy is clearly indicated if not already started and where intensive lifestyle intervention is unambiguous rather than advisory.

• CAC 300 or higher: Extensive plaque. High-intensity statin therapy is guideline-indicated. Additional investigation and specialist involvement are appropriate.

The clinical power of the CAC score in this context is that it answers a different question than any blood test. ApoB tells you how many atherogenic particles are circulating. Lp(a) identifies genetic residual risk. hsCRP reveals inflammatory pathway activity. The CAC score tells you whether any of that particle burden, genetic predisposition, or inflammation has already translated into structural arterial damage. It converts probabilistic risk language into direct anatomical evidence.

A 2018 analysis of MESA data published in the Journal of the American College of Cardiology by Blaha et al. demonstrated that CAC scoring improved cardiovascular risk reclassification significantly beyond traditional risk factors, including the Pooled Cohort Equations. Patients with CAC = 0 were substantially reclassified downward; those with CAC above 100 were substantially reclassified upward. The test added predictive information beyond what any combination of blood markers provided. (doi: 10.1016/j.jacc.2017.11.074)

The ACC/AHA guidelines on the use of CAC in cardiovascular risk assessment, published in 2018, specifically identify CAC scoring as a tool to guide decision-making in patients where the decision to initiate statin therapy is uncertain after traditional risk factor assessment, which describes precisely the patient with “normal cholesterol” who is unsure whether their risk has been characterized. 5 / Solid

A cardiologist ordering a CAC score in a 54-year-old man with LDL of 102 and the metabolic phenotype described in this article is not looking for something to worry about. He is providing the most direct available answer to the question the patient should be asking: has the process that leads to heart attacks already started in my arteries? If the CAC is zero, the answer is no detectable evidence, and that is genuinely good news that a normal LDL alone could not have delivered with the same confidence. If the CAC is 347, as in the patient at the start of this article, the answer reframes every subsequent decision, and normal LDL is understood for what it was: one measurement of one risk factor, not a clearance of the coronary arteries.

What to Do This Week

1. Ask your physician to add ApoB to your next lipid panel. The request is specific: “I would like ApoB added to my lipid order.” The argument for it is straightforward: it is more predictive than LDL for a large fraction of patients, the evidence base is strong, and the additional cost is minimal. Most major reference laboratories run it as a standard test.

2. Know your waist circumference before you go. If it is above 40 inches, you fit the metabolic phenotype where discordance between LDL and ApoB is most common and most consequential. This fact should inform how seriously you and your physician treat an otherwise acceptable LDL.

3. If your LDL is described as “normal” but your physician also mentions borderline triglycerides, low HDL, or tells you to watch your diet, ask specifically about ApoB. The combination of borderline triglycerides and low HDL is the lipid signature of the high-discordance phenotype. That is the moment to push for the number that resolves the ambiguity.

4. Know your ApoB target before the result arrives. Below 90 mg/dL is the general primary prevention target for most adults. Below 70 mg/dL applies when risk factors are present, including metabolic syndrome, hypertension, family history of premature cardiovascular disease, or a CAC score above zero. Below 55 mg/dL applies to patients with established cardiovascular disease or very high calculated 10-year risk.

5. If your CAC score has never been done and you are over 45 with any metabolic risk factors, ask about scheduling it. The coronary artery calcium score is a low-dose CT scan that takes under 15 minutes and directly reveals whether elevated particle burden has already translated into coronary plaque. It is the test that converts a probabilistic risk estimate into direct anatomical evidence.

The standard cholesterol panel was designed in an era when LDL was the only practical lipid measurement available and the evidence for ApoB had not yet accumulated. The panel has not been updated to reflect the evidence that has emerged since. ApoB is inexpensive, widely available, and measures the construct that directly predicts cardiovascular events. Asking for it is the single most useful thing a patient with “normal cholesterol” can do before concluding that their risk has been fully characterized.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.